PR Newswire Clinical TrialsOriginal article
Pulnovo Medical Announces Results of the PADN-HF-PH Trial at ESC Congress 2026, Simultaneously Published in The New England Journal of Medicine (NEJM)
Data ReadoutpositivePositive
AI Analysis
Summary
Pulnovo Medical announced positive Phase 3 PADN-HF-PH trial results in 264 PH-LHD patients showing 51% reduction in clinical worsening risk and 35.5% decrease in recurrent events, simultaneously published in NEJM.
Clinical Trial Data
Primary Endpoint
Met
Patients
264
Outcome Details
51% reduction in risk of clinical worsening, 35.5% decrease in recurrent clinical events, sustained improvements in functional capacity
Importance:7/10
Sentiment:
0.80
Phase 3Clinical Trial ResultsNEJM PublicationESC CongressPH-LHDPulmonary Hypertension
Read the original article
Published by PR Newswire Clinical Trials on September 3, 2026 11:53 AM